Category Archives: Drug pricing

Importation a cliché, not a CAPA

The right hand not knowing what the left hand’s doing. Robbing Peter to pay Paul. Talking out of both sides of the mouth. . . . They’re all clichés that aptly describe how the U.S. Congress too often works. Especially…

Share

Life and death and #BIO2017

I missed BIO this year – the first time in 40 years as a journalist that I canceled attendance at a major conference due to a death in the family. About 12 hours before I was due to board a…

Share

No choice, no free market

Inundated with heart-wrenching stories about constituents who can’t afford the prescription drugs they need to live, U.S. lawmakers spend a lot of time lamenting a free market that isn’t working and then debating ways to “fix” it. Reality check: A…

Share

Myth busters take on drug prices, or do they?

Hoping to debunk biopharma’s biggest justification for high drug prices, Public Citizen released a report Monday showing that the 20 biggest drug companies collectively generated more than $100 billion in annual profits from 2013 through 2015, nearly double what a…

Share

Is ‘what the patient pays’ the right barometer for pricing drugs?

Just a few months ago, Mylan NV got caught in a net of its own making when it raised the U.S. list price for a two-pack of its Epipen to $608, a 550 percent increase over several years. The hue…

Share

Yes, there’s a doctor in the House (and Senate)

It was out with the old and in with the new Tuesday as the 114th U.S. Congress gave way to the 115th. Among the new delegates taking their seats in the House were a few more doctors, a dentist and…

Share

Rules of the PAP road not always clear, even to seasoned travelers

As a veteran health care journalist, I appreciate the need for biopharmas to recoup R&D costs and to operate profitably, so it’s hardly surprising to me when newly approved drugs are priced at a premium. But I’m also a consumer…

Share

An end to Charlotte’s web?

In the annals of popular literature, TV shows and movie scripts, only a handful of pigs have achieved mega stardom: Napoleon, who took over a farm and assassinated his political rivals; Arnold, who epitomized the couch potato at Green Acres;…

Share

Shkreli: A supervillain with a dastardly plan? Or a distraction from the real problem?

As the saga of Martin Shkreli continues to unfold in all its obnoxious glory, with every tweet and smirk signifying the former biopharma CEO’s apparent aspirations to a level of sheer jerkiness heretofore unseen on planet Earth, there’s one question…

Share

Better Rx needed to treat drugmakers’ PR malady

Biopharma has a bad PR disease. The diagnosis is pretium offensus, otherwise known as “sticker shock.” The infectious condition has two causes: enormous, inexplicable, overnight price hikes and six-figure drug prices that spread from headlines to become a viral meme…

Share